News

11/02/2026 in Company News, Homepage News, News Highlight, RAG-01

Ractigen Therapeutics Kicks Off Multi-Center Phase II Clinical Trial of First-in-Class saRNA Therapeutic RAG-01 for Non-Muscle Invasive Bladder Cancer

Trial initiated at Fudan University Shanghai Cancer Center (FUSCC) under the leadership of Leading Principal…
Read More
10/23/2026 in Company News, Homepage News, Industry News, News Highlight

Ractigen Therapeutics Publishes Foundational Study on its Extrahepatic LiCO™ Delivery Platform in Molecular Therapy – Nucleic Acids

Peer-reviewed study demonstrates potent, multi-month extrahepatic delivery via both systemic administration—targeting skeletal muscle, heart, and…
Read More
10/03/2026 in Company News, Homepage News, Industry News, News Highlight

Ractigen Therapeutics Presents Positive First-in-Human Data for RAG-18 at WMS 2026, Establishing Clinical Proof-of-Mechanism for RNA Activation in Duchenne Muscular Dystrophy

First clinical evidence demonstrating that a systemically delivered small activating RNA (saRNA) can safely upregulate…
Read More
09/15/2026 in Company News, Homepage News, Industry News, News Highlight

Ractigen Therapeutics to Present First-in-Human RNA Activation Data in Duchenne Muscular Dystrophy as a Late-Breaking Oral Presentation at the 31st Annual Congress of the World Muscle Society

Late-Breaking selection at the 31st Annual World Muscle Society Congress — a designation reserved for…
Read More